The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 05, 2014
Filed:
May. 02, 2008
Richard W. Compans, Atlanta, GA (US);
Baozhong Wang, Atlanta, GA (US);
Beatrice Hahn, Birmingham, AL (US);
Weimin Liu, Hoover, AL (US);
Gale Smith, Gaithersburg, MD (US);
Peter Pushko, Frederick, MD (US);
Richard W. Compans, Atlanta, GA (US);
Baozhong Wang, Atlanta, GA (US);
Beatrice Hahn, Birmingham, AL (US);
Weimin Liu, Hoover, AL (US);
Gale Smith, Gaithersburg, MD (US);
Peter Pushko, Frederick, MD (US);
Emory University, Atlanta, GA (US);
The UAB Research Foundation, Birmingham, AL (US);
Novavax, Inc., Rockville, MD (US);
Abstract
Embodiments of the present disclosure encompasses virus-like particles, methods of making virus-like particles, including expression vectors, wherein the virus-like particles may comprise enhanced levels of capsid-bound a chimeric HN-Env polypeptide compared to VLPs derived from unmodified HIV-env polypeptides. Embodiments of the virus-like particle may have Env-specific epitopes exposed on the outer surface thereof. In one embodiment, the Env-specific epitopes exposed on the outer surface of the virus-like particle may specifically bind with an anti-HIV-Env specific antibody. Embodiments of the disclosure further includes methods of generating an antibody specific to an epitope of an HIV-Env polypeptide, comprising delivering to an animal or a human an effective amount of a suspension of virus-like particles comprising a chimeric HIV-Eny polypeptide, thereby inducing the formation of an antibody specific to an epitope of an HIV-1 eny polypeptide.